Skip to main content
. 2017 Feb 20;7:42683. doi: 10.1038/srep42683

Figure 7. PT-Mangiferin reduces inflammation by inactivating NLRP3 inflammasome.

Figure 7

(A) cDNA obtained from RAW 264.7 cells with different treatments as described in material and methods were analyzed for expression of NLRP3, Caspase-1 and IL-1β at transcription level. GAPDH was used as positive control. (B) Analysis of expression of NLRP3, Caspase-1 and IL-1β in RAW 264.7 cells at protein level. β-actin was used as internal positive control. (C) Analysis of IL-1β and IL-18 by ELISA in the culture supernatants of RAW264.7 cells. (D) cDNA obtained from air pouch tissues with different treatments were analyzed for expression of NLRP3, Caspase-1 and IL-1β α at transcription level as described in material and methods. GAPDH was used as positive control. (E) Analysis of expression of NLRP3, Caspase-1 and IL-1β from air pouch tissues at protein level. β-actin was used as internal positive control. Data are mean ± SEM and representative of three independent experiments. *P < 0.05 PBS- Phosphate buffer saline, LPS-Lipopolysaccharide (1 μg/ml), CXB- Celecoxib (20 μM), MF-20- PT-Mangiferin (20 μM), MF-40- PT-Mangiferin (40 μM), CGN- Carrageenan (1.5%, 0.5 ml), CXB-Celecoxib (10 mg/kg body weight), MF-10- PT-Mangiferin at 10 mg/kg body weight, MF-20- PT-Mangiferin at 20 mg/kg body weight.